At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
FX006 10 mg +2 moredrug
Likely dose
FX006 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee
In Brief
A Phase 2 clinical trial evaluating FX006 10 mg, FX006 40 mg, and 1 other intervention for Osteoarthritis of the Knee. Completed, enrolled 50 participants across 3 sites.
Detailed Summary
The purpose of this study was to characterize the local duration of exposure of TCA for 2 doses of FX006 relative to 40 mg of TCA IR in patients with OA of the knee.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedDec 2013
Primary CompletionApr 2014
TodayJul 2026
First PostedDec 6, 2013
Enrollment StartNov 1, 2013
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.6 years ago
Interventions
FX006 10 mgdrug
Extended-release formulation
FX006 40 mgdrug
Extended-release formulation
TCA IR 40 mgdrug
Immediate-release formulation